Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial

Abdou Amza, Boubacar Kadri, Beido Nassirou, Sun Y Cotter, Nicole E Stoller, Sheila K West, Robin L Bailey, Travis C Porco, Bruce D Gaynor, Jeremy D Keenan, Thomas M Lietman, Catherine E Oldenburg
2017 British Journal of Ophthalmology  
background/aims The WHO recommends 3-5 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. Here, we assess the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger. Methods Twenty-four communities were randomised to a single day of azithromycin distribution with a coverage target of 80% of the community or up to 4 days of treatment,
more » ... ng for greater than 90% coverage. Distributions were annual and individuals above 6 months of age were treated. Children under 5 years of age were monitored for ocular chlamydia infection and active trachoma. results At baseline, ocular chlamydia prevalence was 20.5% (95% CI 9.8% to 31.2%) in the standard coverage arm and 21.9% (95% CI 11.3% to 32.5%) in the enhanced coverage arm, which reduced to 4.6% (95% CI 0% to 9.5%, p=0.008) and 7.1% (95% CI 2.7% to 11.4%, p<0.001) at 36 months, respectively.
doi:10.1136/bjophthalmol-2017-310916 pmid:28893761 fatcat:ya3h4woklbdadmyks4nkme3ibe